A Population Pharmacokinetic and Exposure–Response Analysis for Baricitinib in Pediatric Patients with Atopic Dermatitis
Clinical Pharmacokinetics · 2026
DOI: 10.1007/s40262-025-01563-8 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacokinetics, 2026. Verfasst von Rodney L Decker und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Purines, Azetidines, Dermatitis, Atopic, Sulfonamides. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
BACKGROUND: Baricitinib is approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy and has received regulatory authorization in Europe for moderate-to-severe AD in patients 2 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, IN, USA.
- Metrum Research Group, Tariffville, CT, USA.
- Eli Lilly and Company, Indianapolis, IN, USA. zhang_xin_xz@lilly.com.
- Lilly Corporate Center, Indianapolis, IN, 46285, USA. zhang_xin_xz@lilly.com.
ORCID-Profile: Xin Zhang
Förderung
- Eli Lilly and Company
Zitieren
APA
Decker, R. L., Ernest, C. S., Radtke, D. B., Prakash, A., & Zhang, X. (2026). A Population Pharmacokinetic and Exposure–Response Analysis for Baricitinib in Pediatric Patients with Atopic Dermatitis. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01563-8
Vancouver
Decker RL, Ernest CS, Radtke DB, Prakash A, Zhang X. A Population Pharmacokinetic and Exposure–Response Analysis for Baricitinib in Pediatric Patients with Atopic Dermatitis. Clinical Pharmacokinetics. 2026. doi:10.1007/s40262-025-01563-8
BibTeX
@article{Decker2026,
author = {Decker, Rodney L and Ernest, C Steven and Radtke, David B and Prakash, Apurva and Zhang, Xin},
title = {A Population Pharmacokinetic and Exposure–Response Analysis for Baricitinib in Pediatric Patients with Atopic Dermatitis},
journal = {Clinical Pharmacokinetics},
year = {2026},
doi = {10.1007/s40262-025-01563-8}
}
EUVIMED